title: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
abstract: OBJECTIVE
  To assess the tolerability and pharmacokinetic profile of single and repeat doses of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
  
  
  METHODS
  A total of 31 subjects participated in two placebo-controlled, rising-dose studies. The first study assessed the pharmacokinetics and tolerability of single doses of marimastat of 25, 50, 100, 200, 400 and 800 mg. In the second study, continuous dosing over 6.5 days with three incremental dose levels of 50, 100 and 200 mg twice daily was assessed. Full pharmacokinetic profiles were obtained on days 0 and 6, and trough concentrations were measured on all days. For each pharmacokinetic profile in the studies, summary measures including Cmax, tmax, elimination half-life and AUC were calculated. Urinary drug weights were also measured. All adverse events were documented, and haematological and biochemical variables, vital signs and ECGs were monitored throughout the study.
  
  
  RESULTS
  Peak plasma concentrations were observed at 1.5-3 h for all subjects at all doses. Peak levels were approximately proportional to dose, as was drug exposure as calculated by AUC. Data from both studies indicate that the terminal elimination half-life is of the order of 8-10 h, and that there is no unexpected drug accumulation. Marimastat was well-tolerated, with adverse effects being mild and occurring with similar frequency to placebo. Small but reversible elevations in liver transaminases were noted with repeat dosing of marimastat, the most significant of these occurring at a dose of 200 mg twice daily.
  
  
  CONCLUSIONS
  Single and repeat oral doses of marimastat in healthy male subjects appear to be well-tolerated. The drug is rapidly absorbed with high peak levels achieved. It has a terminal elimination half-life of 8-10 h which would support twice daily dosing in further clinical trials.
authors.affiliation: British Biotech Pharmaceuticals Ltd., Oxford.
authors.forename: A W
authors.initials: AW
authors.lastname: Millar
authors.forename: P D
authors.initials: PD
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Moore
authors.forename: W A
authors.initials: WA
authors.lastname: Galloway
authors.forename: A G
authors.initials: AG
authors.lastname: Cornish
authors.forename: T J
authors.initials: TJ
authors.lastname: Lenehan
authors.forename: K P
authors.initials: KP
authors.lastname: Lynch
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D006877:Hydroxamic Acids; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D010919:Placebos
chemical_list: D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D010919:Placebos; C100342:marimastat; D008666:Metalloendopeptidases